https://www.selleckchem.com/products/blu9931.html
This phase 2 study examined the efficacy and safety of tolvaptan, an aquaretic drug, in the treatment of ascites associated with cancer. In the dose-escalation phase, oral tolvaptan was initiated at a dose of 3.75mg/day, and the dose was increased daily to 7.5, 15 and 30mg/day. Dose escalation was terminated once the increase from baseline in the daily urine volume reached 500ml, at which point the patient proceeded to the maintenance phase of 5-7days. Improvement of ascites was determined primarily by reduction in body weight and ascit
Like
Comment
Share
